| Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial GD Demetri, AT van Oosterom, CR Garrett, ME Blackstein, MH Shah, ... The Lancet 368 (9544), 1329-1338, 2006 | 3060 | 2006 |
| Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib TF Chu, MA Rupnick, R Kerkela, SM Dallabrida, D Zurakowski, L Nguyen, ... The Lancet 370 (9604), 2011-2019, 2007 | 1164 | 2007 |
| Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors CP Raut, M Posner, J Desai, JA Morgan, S George, D Zahrieh, ... Journal of Clinical Oncology 24 (15), 2325-2331, 2006 | 565 | 2006 |
| Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors J Desai, L Yassa, E Marqusee, S George, MC Frates, MH Chen, ... Annals of internal medicine 145 (9), 660-664, 2006 | 456 | 2006 |
| Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure S George, JY Blay, PG Casali, A Le Cesne, P Stephenson, SE Deprimo, ... European journal of cancer 45 (11), 1959-1968, 2009 | 434 | 2009 |
| Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors AJ Wagner, I Malinowska-Kolodziej, JA Morgan, W Qin, CDM Fletcher, ... Journal of clinical oncology 28 (5), 835, 2010 | 408 | 2010 |
| Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas S George, P Merriam, RG Maki, AD Van den Abbeele, JT Yap, T Akhurst, ... Journal of Clinical Oncology 27 (19), 3154, 2009 | 350 | 2009 |
| Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial S George, Q Wang, MC Heinrich, CL Corless, M Zhu, JE Butrynski, ... Journal of Clinical Oncology 30 (19), 2401, 2012 | 282 | 2012 |
| Breakpoints of the t (11; 18)(q21; q21) in mucosa-associated lymphoid tissue (MALT) lymphoma lie within or near the previously undescribed gene MALT1 in chromosome 18 JA Morgan, Y Yin, AD Borowsky, F Kuo, N Nourmand, JI Koontz, ... Cancer research 59 (24), 6205-6213, 1999 | 208 | 1999 |
| A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib TV Patel, JA Morgan, GD Demetri, S George, RG Maki, M Quigley, ... Journal of the National Cancer Institute 100 (4), 282-284, 2008 | 197 | 2008 |
| Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid TumorsPhase I Study of Everolimus and … R Quek, Q Wang, JA Morgan, GI Shapiro, JE Butrynski, N Ramaiya, ... Clinical Cancer Research 17 (4), 871-879, 2011 | 186 | 2011 |
| Immunotherapy with single agent nivolumab for advanced leiomyosarcoma of the uterus: results of a phase 2 study E Ben‐Ami, CM Barysauskas, S Solomon, K Tahlil, R Malley, M Hohos, ... Cancer 123 (17), 3285-3290, 2017 | 181 | 2017 |
| Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors GD Demetri, P Lo Russo, IRJ MacPherson, D Wang, JA Morgan, ... Clinical Cancer Research 15 (19), 6232-6240, 2009 | 166 | 2009 |
| Molecular Target Modulation, Imaging, and Clinical Evaluation of Gastrointestinal Stromal Tumor Patients Treated with Sunitinib Malate after Imatinib FailureSunitinib Treatment … GD Demetri, MC Heinrich, JA Fletcher, CDM Fletcher, ... Clinical Cancer Research 15 (18), 5902-5909, 2009 | 166 | 2009 |
| SU11248, a multi-targeted tyrosine kinase inhibitor, can overcome imatinib (IM) resistance caused by diverse genomic mechanisms in patients (pts) with metastatic … GD Demetri, J Desai, JA Fletcher, JA Morgan, CDM Fletcher, ... Journal of Clinical Oncology 22 (14_suppl), 3001-3001, 2004 | 160 | 2004 |
| Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy E Choy, JE Butrynski, DC Harmon, JA Morgan, S George, AJ Wagner, ... BMC cancer 14 (1), 1-6, 2014 | 156 | 2014 |
| Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors J Desai, S Shankar, MC Heinrich, JA Fletcher, CD Fletcher, J Manola, ... Clinical Cancer Research 13 (18), 5398-5405, 2007 | 147 | 2007 |
| A phase I–II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors P Schöffski, P Reichardt, JY Blay, H Dumez, JA Morgan, I Ray-Coquard, ... Annals of oncology 21 (10), 1990-1998, 2010 | 141 | 2010 |
| Results from a continuation trial of SU11248 in patients (pts) with imatinib (IM)-resistant gastrointestinal stromal tumor (GIST) RG Maki, JA Fletcher, MC Heinrich, JA Morgan, S George, J Desai, ... Journal of Clinical Oncology 23 (16_suppl), 9011-9011, 2005 | 139 | 2005 |
| Leiomyosarcoma of the inferior vena cava: survival after aggressive management H Ito, JL Hornick, MM Bertagnolli, S George, JA Morgan, EH Baldini, ... Annals of surgical oncology 14, 3534-3541, 2007 | 129 | 2007 |
